The hostile bid from Curaleaf introduces significant uncertainty. Monitor the Special Committee's formal recommendation and any competing bids. The 105-day offer window suggests a protracted process; the stock may trade on bid speculation and the outcome of the strategic review.
Price Chart
Executive Summary
Aurora Cannabis filed a 6-K responding to Curaleaf Holdings' hostile takeover bid, correcting what it calls inaccurate statements about its business. The company reported 17% YoY international net revenue growth in fiscal Q1'27 and record global medical cannabis revenue and adjusted EBITDA in FY2026. Aurora's board and a special committee are reviewing the offer, advising shareholders to take no action pending a formal recommendation.
Key Facts
- Aurora reported 17% year-over-year international net revenue growth in fiscal Q1'27.
- Aurora delivered record global medical cannabis revenue and adjusted EBITDA results in FY2026.
- Aurora's Board and a Special Committee are reviewing Curaleaf's unsolicited hostile bid.
- Aurora acquired Internode Pharma Limited and HAP Pharma Limited on August 19, 2026, expanding direct distribution in the UK.
- Curaleaf's offer remains open for at least 105 days from its launch.
- Aurora holds the #1 market share position by revenue in Poland.
- The German reimbursement market segment accounted for less than 10% of Aurora's total German volume prior to regulatory changes.
- Aurora has increased its EU-GMP production capacity by more than 40% over the past five years.
Financial Impact
International net revenue up 17% YoY in Q1'27; record global medical cannabis revenue and adjusted EBITDA in FY2026.
Risk Factors
- Hostile bid may fail or be at an inadequate price, leading to stock price decline.
- Curaleaf may withdraw or reduce its offer if due diligence reveals issues.
- Aurora's standalone execution risk if the bid is rejected and no superior offer emerges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000817 |
| Document: 0001279569-26-000817-index-headers.html | 0001279569-26-000817 |
| Document: 0001279569-26-000817-index.html | 0001279569-26-000817 |
| Document: 0001279569-26-000817.txt | 0001279569-26-000817 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.87 | awaiting T+5 | — | $3.90 (+0.78%) |
Oct 14, 2026 12d ago | 6-K | $4.10 $3.97 | ▼ −3.17% | ▼ −2.16% | $3.90 (−4.88%) |
Oct 8, 2026 18d ago | 6-K | $4.43 $4.10 | ▼ −7.45% | ▼ −7.17% | $3.90 (−11.96%) |
Oct 6, 2026 20d ago | 6-K | $4.46 $4.17 | ▼ −6.50% | ▼ −5.52% | $3.90 (−12.56%) |
Oct 5, 2026 21d ago | 6-K | $4.59 $4.29 | ▼ −6.54% | ▼ −6.40% | $3.90 (−15.03%) |
Sep 16, 2026 5w ago | 6-K | $3.83 $4.22 | ▲ +10.18% | ▲ +7.62% | $3.90 (+1.83%) |
Sep 14, 2026 6w ago | 6-K | $3.81 $4.03 | ▲ +5.77% | ▲ +5.67% | $3.90 (+2.36%) |
Sep 9, 2026 6w ago | 6-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.63% | $3.90 (+0.52%) |
Sep 2, 2026 7w ago | 6-K | $4.03 $3.73 | ▼ −7.44% | ▼ −6.49% | $3.90 (−3.23%) |
Aug 24, 2026 9w ago | 6-K | $3.94 $4.05 | ▲ +2.79% | ▲ +2.32% | $3.90 (−1.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers